266 related articles for article (PubMed ID: 15955736)
1. Targeting the DNA repair defect of BRCA tumours.
Turner N; Tutt A; Ashworth A
Curr Opin Pharmacol; 2005 Aug; 5(4):388-93. PubMed ID: 15955736
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
3. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Wang W; Figg WD
Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
[TBL] [Abstract][Full Text] [Related]
4. The biological effects and clinical implications of BRCA mutations: where do we go from here?
Stoppa-Lyonnet D
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
[TBL] [Abstract][Full Text] [Related]
5. Homologous repair of DNA damage and tumorigenesis: the BRCA connection.
Jasin M
Oncogene; 2002 Dec; 21(58):8981-93. PubMed ID: 12483514
[TBL] [Abstract][Full Text] [Related]
6. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
7. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks.
Nagaraju G; Scully R
DNA Repair (Amst); 2007 Jul; 6(7):1018-31. PubMed ID: 17379580
[TBL] [Abstract][Full Text] [Related]
8. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
10. Functions of BRCA1 and BRCA2 in the biological response to DNA damage.
Venkitaraman AR
J Cell Sci; 2001 Oct; 114(Pt 20):3591-8. PubMed ID: 11707511
[TBL] [Abstract][Full Text] [Related]
11. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
Sowter HM; Ashworth A
Carcinogenesis; 2005 Oct; 26(10):1651-6. PubMed ID: 15917310
[TBL] [Abstract][Full Text] [Related]
13. In brief: BRCA1 and BRCA2.
Foulkes WD; Shuen AY
J Pathol; 2013 Aug; 230(4):347-9. PubMed ID: 23620175
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
Fridlich R; Annamalai D; Roy R; Bernheim G; Powell SN
DNA Repair (Amst); 2015 Jun; 30():11-20. PubMed ID: 25836596
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
[TBL] [Abstract][Full Text] [Related]
16. BRCA gene structure and function in tumor suppression: a repair-centric perspective.
Murphy CG; Moynahan ME
Cancer J; 2010; 16(1):39-47. PubMed ID: 20164689
[TBL] [Abstract][Full Text] [Related]
17. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
19. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Vollebergh MA; Jonkers J; Linn SC
Cell Mol Life Sci; 2012 Jan; 69(2):223-45. PubMed ID: 21922196
[TBL] [Abstract][Full Text] [Related]
20. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
